Clinical study of Ebastine and Ranitidine combined with Compound Glycyrrhizin Tablets in the treatment of chronic urticaria
YANG Cheng-yu1 YU Jin-song2
1.Hengfeng County Center for Prevention and Treatment of Dermatology and Venereology,in Shangrao City of Jiangxi Province,Hengfeng 334300,China;
2.Department of Dermatology and STD,Yiyang County People′s Hospital in Shangrao City of Jiangxi Province,Yiyang 334300,China
Abstract:ObjectiveTo investigate the clinical effect of Ebastine and Ranitidine combined with Compound Glycyrrhizin Tablets in the treatment of chronic urticaria.Methods80 patients of Chronic urticaria who were admitted to our hospital from November 2016 to March 2017 were selected.According to the random balancing sequencing method,the patients were divided into control group and observation group,40 cases in each up.The control group was given Ebastine combined with Ranitidine,and the observation group was further given Compound Glycyrrhizin Tablets on the basis of the control group.The serum total IgE level,clinical efficacy,adverse reactions and other related indicators were observed after the treatment.ResultsThe decreasing speed of the level of serum IgE in the observation group was faster than that in the control group,and the clinical curative effect was better than that in the control group;the occurrence of adverse reactions was less than that in the control group,without serious adverse reactions.There was significant difference between the two groups(P<0.05).ConclusionIn the treatment of chronic urticaria,the application of ebastine and ranitidine combined with compound glycyrrhizin tablets can significantly improve the clinical curative effect of patients,with ideal safety,which is worthy of clinical application and promotion in the treatment of urticaria.
杨成裕;俞劲松. 依巴斯汀、雷尼替丁联合复方甘草酸甘片治疗慢性荨麻疹的临床研究[J]. 中国当代医药, 2017, 24(33): 69-71.
YANG Cheng-yu;YU Jin-song. Clinical study of Ebastine and Ranitidine combined with Compound Glycyrrhizin Tablets in the treatment of chronic urticaria. 中国当代医药, 2017, 24(33): 69-71.